Reig Timeline


Agreement with the European Commission to reserve vaccine production capacity
15 million units of intravenous anesthetic in Japan
Agreement with the international NGO Farmamundi


Launch of Forte Pharma E-commerce in China
New patented CicloTech® trans-ungual release technology
Launch of RegeNail®, with CicloTech® technology
Launch of DexULac®, with CicloTech® technology
Completed co-development of TRIFERTY-ATM®


Creation of RJ Poland
RJ Sweden Extension


Agreement reached with Janssen Pharmaceutical Companies of Johnson & Johnson, for the technology transfer of the production of its COVID-19 Ad26.COV2-S vaccine.


Acquisition of the Joint Health and Pain product portfolio from Bioiberica company.
Collaboration agreements in the development of new products.
Market entry in South Korea with the injectable for hospital use Remifentanil.


Constitution of the joint venture Syna Therapeutics, for the development of biopharmaceutical products in the field of biosimilars and innovative molecules.
Marketing of injectable products begins in Indonesia.


Marketing of injectable products begins in Japan and Forté Pharma products in Hong Kong and Macao.
Industrial development of biotechnological assets.
Marketing of antibiotics begins in the Philippines.


Reig Jofre merges with the company Natraceutical, a benchmark in Europe in the sector of nutritional supplements for sale in pharmacies through its Forté Pharma brand and becomes the 5th Spanish pharmaceutical company by turnover, listed on the Spanish stock market


Acquisition of an international logistics center in Spain.
Creation of RJ Europe, a joint-venture in Singapore for marketing in ASEAN countries.
Creation of RJ UK to centralize Reig Jofre’s commercial activity in the United Kingdom.

  • Acquisition of Swedish company Bioglan AB
  • From export to direct international presence

Antibiotic specialization

  • 2000 acquisition of the Toledo plant
  • 2003 Construction of the Cephalosporin plant
  • 2004 Acquisition of antibiotic licenses Anaclosil, Pulmictan, Ardine and ArdineClav

Specialization in sterile injectables

  • 1978 First freeze dryer
  • 1998 Acquisition of Sant Joan Despí plant
  • 2009 New vial plant

Creation of a portfolio of prescription and OTC products in dermatology and respiratory through the combination of own developments and various acquisitions in Spain


Foundation in Barcelona (Spain) by the pharmacist Ramon Reig Jofre. Current CEO is the third generation of the Reig family.